[Skip to Content]
[Skip to Content Landing]
Views 234
Citations 0
Original Investigation
May 11, 2017

Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic LeukemiaA Meta-analysis

Author Affiliations
  • 1Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston
  • 2CCS Associates, Inc
  • 3University of Texas Health Science Center at Houston, Houston
  • 4US Food and Drug Administration, Rockville, Maryland
  • 5University of Washington School of Medicine, St Louis, Missouri
  • 6US National Cancer Institute, Bethsaida, Maryland
  • 7Inova Fairfax Hospital
  • 8Fred Hutchinson Cancer Research Center, Seattle, Washington
JAMA Oncol. Published online May 11, 2017. doi:10.1001/jamaoncol.2017.0580
Key Points

Question  What role does minimal residual disease (MRD) status have in acute lymphoblastic leukemia (ALL)?

Findings  We used prospective inclusion criteria to identify 39 studies with 13 637 patients. For both pediatric and adult patients with ALL, MRD negativity was associated with much better long-term outcome. For example, 10-year event-free survival for MRD negativity vs MRD was 77% vs 32% for pediatrics and 64% vs 21% for adults.

Meaning  In patients with ALL, MRD status is a useful indicator of therapeutic benefit in clinical practice and has potential for making drug development more efficient by providing early evidence of treatment benefit.

Abstract

Importance  Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD status following induction therapy in patients with acute lymphoblastic leukemia (ALL) with relapse and mortality may improve the efficiency of clinical trials and accelerate drug development.

Objective  To quantify the relationships between event-free survival (EFS) and overall survival (OS) with MRD status in pediatric and adult ALL using publications of clinical trials and other databases.

Data Sources  Clinical studies in ALL identified via searches of PubMed, MEDLINE, and clinicaltrials.gov.

Study Selection  Our search and study screening process adhered to the PRISMA Guidelines. Studies that addressed EFS or OS by MRD status in patients with ALL were included; reviews, abstracts, and studies with fewer than 30 patients or insufficient MRD description were excluded.

Data Extraction and Synthesis  Study sample size, patient age, follow-up time, timing of MRD assessment (post-induction or consolidation), MRD detection method, phenotype/genotype (B cell, T cell, Philadelphia chromosome), and EFS and OS. Searches of PubMed and MEDLINE identified 566 articles. A parallel search on clinicaltrials.gov found 67 closed trials and 62 open trials as of 2014. Merging results of 2 independent searches and applying exclusions gave 39 publications in 3 arms of patient populations (adult, pediatric, and mixed). We performed separate meta-analyses for each of these 3 subpopulations.

Results  The 39 publications comprised 13 637 patients: 16 adult studies (2076 patients), 20 pediatric (11 249 patients), and 3 mixed (312 patients). (The EFS hazard ratio (HR) for achieving MRD negativity is 0.23 (95% Bayesian credible interval [BCI] 0.18-0.28) for pediatric patients and 0.28 (95% BCI, 0.24-0.33) for adults. The respective HRs in OS are 0.28 (95% BCI, 0.19-0.41) and 0.28 (95% BCI, 0.20-0.39). The effect was similar across all subgroups and covariates.

Conclusions and Relevance  The value of having achieved MRD negativity is substantial in both pediatric and adult patients with ALL. These results are consistent across therapies, methods of and times of MRD assessment, cutoff levels, and disease subtypes. Minimal residual disease status warrants consideration as an early measure of disease response for evaluating new therapies, improving the efficiency of clinical trials, accelerating drug development, and for regulatory approval. A caveat is that an accelerated approval of a particular new drug using an intermediate endpoint, such as MRD, would require confirmation using traditional efficacy endpoints.

×